Pandji Irani Fianza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Pandji Irani Fianza has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Anita Rahmawati
Department of Biomedical Science, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
3 shared publications Dimmy Prasetya
Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, Indonesia
2 shared publications- Djatnika Setiabudi
Department of Child Health, Faculty of Medicine, Universitas Padjadjaran/Hasan Sadikin General Hospital, Bandung, West Java, Indonesia
2 shared publications - Mas Rizky Anggun Adipurna Syamsunarno
Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
2 shared publications - Mohammad Ghozali
Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Jatinangor, West Java, Indonesia
2 shared publications Ramdan Panigoro
Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia
2 shared publications
Latest Publications
- Open Access
- 21 July 2026
- Published by Springer Nature in Research Square
Correlation Between Platelet Indices and Residual Cancer Burden Score in Patients with Locally Advanced Luminal B HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Background Luminal B HER2-negative breast cancer often shows an incomplete pathological response after neoadjuvant chemotherapy. Residual Cancer Burden (RCB) is a standardized histopathological tool used to quantify post-treatment residual disease and has prognostic value after neoadjuvant therapy. Platelets interact with tumor cells through inflammatory, angiogenic, and metastatic pathways, and these interactions may be reflected by platelet indices, including mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The relationship between platelet indices and RCB in locally advanced Luminal B HER2-negative breast cancer has not been specifically evaluated in Indonesia. Methods This was an observational analytic study with a cross-sectional design using secondary data from patients with locally advanced Luminal B HER2-negative breast cancer who received neoadjuvant chemotherapy at Dr. Hasan Sadikin General Hospital, Bandung, during 2021–2025. Eligible patients were adult women who had completed neoadjuvant chemotherapy and subsequent mastectomy, with available pre-treatment platelet index data and sufficient pathology information to calculate RCB. A total of 106 patients were included. Bivariate and comparative analyses were performed to assess the correlation between MPV, PDW, PCT, and RCB score. Results Bivariate analysis in 106 patients showed weak correlations between platelet indices and RCB score, with correlation coefficients of -0.050 for MPV (p = 0.420), -0.079 for PDW (p = 0.420), and 0.079 for PCT (p = 0.421). Categorical analysis also showed no significant association between MPV, PDW, or PCT categories and RCB group (all p > 0.05). Comparative analysis across RCB groups similarly demonstrated no significant differences in MPV, PDW, or PCT. Conclusions Pre-treatment platelet indices were not significantly correlated with RCB score in patients with locally advanced Luminal B HER2-negative breast cancer receiving neoadjuvant chemotherapy. These findings suggest that MPV, PDW, and PCT are not reliable standalone biomarkers for estimating residual tumor burden in this setting. Further studies incorporating other hematologic and inflammatory parameters are warranted.
- 21 July 2026
- Published by Springer Nature in Research Square
Open AccessCorrelation Between Platelet Indices and Residual Cancer Burden Score in Patients with Locally Advanced Luminal B HER2-Negative Breast Cancer Receiving Neoadjuvant Chemotherapy
Background Luminal B HER2-negative breast cancer often shows an incomplete pathological response after neoadjuvant chemotherapy. Residual Cancer Burden (RCB) is a standardized histopathological tool used to quantify post-treatment residual disease and has prognostic value after neoadjuvant therapy. Platelets interact with tumor cells through inflammatory, angiogenic, and metastatic pathways, and these interactions may be reflected by platelet indices, including mean platelet volume (MPV), platelet distribution width (PDW), and plateletcrit (PCT). The relationship between platelet indices and RCB in locally advanced Luminal B HER2-negative breast cancer has not been specifically evaluated in Indonesia. Methods This was an observational analytic study with a cross-sectional design using secondary data from patients with locally advanced Luminal B HER2-negative breast cancer who received neoadjuvant chemotherapy at Dr. Hasan Sadikin General Hospital, Bandung, during 2021–2025. Eligible patients were adult women who had completed neoadjuvant chemotherapy and subsequent mastectomy, with available pre-treatment platelet index data and sufficient pathology information to calculate RCB. A total of 106 patients were included. Bivariate and comparative analyses were performed to assess the correlation between MPV, PDW, PCT, and RCB score. Results Bivariate analysis in 106 patients showed weak correlations between platelet indices and RCB score, with correlation coefficients of -0.050 for MPV (p = 0.420), -0.079 for PDW (p = 0.420), and 0.079 for PCT (p = 0.421). Categorical analysis also showed no significant association between MPV, PDW, or PCT categories and RCB group (all p > 0.05). Comparative analysis across RCB groups similarly demonstrated no significant differences in MPV, PDW, or PCT. Conclusions Pre-treatment platelet indices were not significantly correlated with RCB score in patients with locally advanced Luminal B HER2-negative breast cancer receiving neoadjuvant chemotherapy. These findings suggest that MPV, PDW, and PCT are not reliable standalone biomarkers for estimating residual tumor burden in this setting. Further studies incorporating other hematologic and inflammatory parameters are warranted.
- Open Access
- 1 April 2024
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 17, 1663-1669
Gender Disparities in Psychological Disturbances and Quality of Life Among Adolescent and Adult Patients with Thalassemia: A Review
Thalassemia is a chronic disease caused by impaired globin chain synthesis, leading to ineffective erythropoiesis, hemolysis, and chronic anemia. The treatment of patients with thalassemia, including blood transfusion combined with chelation therapy has progressed and improved their survival and prognosis. However, thalassemia-related psychological problems and impaired health-related quality of life (QoL) challenges still exist. Gender is one of the factors that has been suggested, to contribute to the disparities in psychological outcomes. This review article examined the evidence for gender differences in psychological disturbances and QoL in adolescent and adult patients with thalassemia. A non-systematic search of the literature was conducted in PubMed and Google Scholar for English full-text available from 2013 to 2023. We identified 23 studies with a sample size ≥ 100 that examined gender disparities in anxiety, depression, and QoL in adolescent and adult patients with thalassemia (mean prevalence of female = 53.1%; mean age = 28 years). Our review shows that there are gender disparities in psychological distress and QoL in adolescent and adult patients with thalassemia. Statistically significant gender differences were demonstrated in 62% of the psychological and QoL outcomes from 16 studies. Female patients had a higher prevalence of anxiety, depression, and poorer QoL in some studies. However, further studies with sufficient power and design are necessary to confirm the existence of gender disparities in psychological disturbances and QoL outcomes.
- 1 April 2024
- Published by Taylor & Francis in Journal of Multidisciplinary Healthcare
- Vol. ume 17, 1663-1669
Open AccessGender Disparities in Psychological Disturbances and Quality of Life Among Adolescent and Adult Patients with Thalassemia: A Review
Thalassemia is a chronic disease caused by impaired globin chain synthesis, leading to ineffective erythropoiesis, hemolysis, and chronic anemia. The treatment of patients with thalassemia, including blood transfusion combined with chelation therapy has progressed and improved their survival and prognosis. However, thalassemia-related psychological problems and impaired health-related quality of life (QoL) challenges still exist. Gender is one of the factors that has been suggested, to contribute to the disparities in psychological outcomes. This review article examined the evidence for gender differences in psychological disturbances and QoL in adolescent and adult patients with thalassemia. A non-systematic search of the literature was conducted in PubMed and Google Scholar for English full-text available from 2013 to 2023. We identified 23 studies with a sample size ≥ 100 that examined gender disparities in anxiety, depression, and QoL in adolescent and adult patients with thalassemia (mean prevalence of female = 53.1%; mean age = 28 years). Our review shows that there are gender disparities in psychological distress and QoL in adolescent and adult patients with thalassemia. Statistically significant gender differences were demonstrated in 62% of the psychological and QoL outcomes from 16 studies. Female patients had a higher prevalence of anxiety, depression, and poorer QoL in some studies. However, further studies with sufficient power and design are necessary to confirm the existence of gender disparities in psychological disturbances and QoL outcomes.
- Open Access
- 1 August 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (8) , 2837-2843
Physician Perceptions of the Clinical, Economic and Humanistic Burden of Disease and Unmet Needs in Myelofibrosis: Preliminary Findings from the MPN Landmark Survey in Indonesia
Background/ Objective: Myelofibrosis (MF) is a severe form of Myeloproliferative Neoplasms (MPNs). It is a rare disease in Indonesia and is reportedly associated with symptoms resulting in poor quality-of-life, pre-mature mortality, disability, and loss of productivity. As the disease is rare, there are limited published information around MF, particularly in Indonesia. Methods: A cross-sectional survey was designed and administered between November and December 2021 among practicing Haematologists-Medical Oncologists who are experienced in treating patients with MF. The objectives of the survey were to assess physician’s understanding of the overall diagnosis of MF, the disease burden, current treatment practices and remaining unmet needs. Outcomes were analysed descriptively. Result: The survey was completed by 30 respondents. The findings suggest that symptom burden is high and has a significant negative impact on quality-of-life. Treatment burden is also high which can result in high healthcare resource utilisation. Physicians expressed need for novel therapeutic options and improved access and coverage for such options. There is also a need to improve access and coverage for JAK V617F testing locally and local hospital infrastructures should be upgraded to ensure MF is accurately diagnosed. Patient may benefit from information on MPN, which may result in earlier presentation, diagnosis and treatment which can improve outcomes. Conclusion: The findings align with previous international research reporting that symptoms and treatment burden are high, and that novel therapeutic options are needed. Additional patient research might be required to better understand the patient experience of MF and how this can be improved.
- 1 August 2023
- Published by EpiSmart Science Vector Ltd in Asian Pacific Journal of Cancer Prevention
- Vol. 24 (8) , 2837-2843
Open AccessPhysician Perceptions of the Clinical, Economic and Humanistic Burden of Disease and Unmet Needs in Myelofibrosis: Preliminary Findings from the MPN Landmark Survey in Indonesia
Background/ Objective: Myelofibrosis (MF) is a severe form of Myeloproliferative Neoplasms (MPNs). It is a rare disease in Indonesia and is reportedly associated with symptoms resulting in poor quality-of-life, pre-mature mortality, disability, and loss of productivity. As the disease is rare, there are limited published information around MF, particularly in Indonesia. Methods: A cross-sectional survey was designed and administered between November and December 2021 among practicing Haematologists-Medical Oncologists who are experienced in treating patients with MF. The objectives of the survey were to assess physician’s understanding of the overall diagnosis of MF, the disease burden, current treatment practices and remaining unmet needs. Outcomes were analysed descriptively. Result: The survey was completed by 30 respondents. The findings suggest that symptom burden is high and has a significant negative impact on quality-of-life. Treatment burden is also high which can result in high healthcare resource utilisation. Physicians expressed need for novel therapeutic options and improved access and coverage for such options. There is also a need to improve access and coverage for JAK V617F testing locally and local hospital infrastructures should be upgraded to ensure MF is accurately diagnosed. Patient may benefit from information on MPN, which may result in earlier presentation, diagnosis and treatment which can improve outcomes. Conclusion: The findings align with previous international research reporting that symptoms and treatment burden are high, and that novel therapeutic options are needed. Additional patient research might be required to better understand the patient experience of MF and how this can be improved.
- Open Access
- 22 July 2022
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 23 (8) , 267
Diagnostic Modalities in Detecting Cardiovascular Complications of Thalassemia
Thalassemia major is the most common monogenetic disorder worldwide, manifested as chronic hemolytic anemia. This condition leads to the need for chronic blood transfusion to be monitored for an iron overload that may be stored in several tissues and organs, including cardiomyocytes, that might cause a broad spectrum of cardiac iron toxicities such as heart failure conduction delays, myocarditis, and arrhythmias. Non-invasive imaging modalities have their benefits and limitations. Each modality complements and generates a comprehensive diagnostic and monitoring of cardiac siderosis in thalassemia major patients.
- 22 July 2022
- Published by IMR Press in Reviews in Cardiovascular Medicine
- Vol. 23 (8) , 267
Open AccessDiagnostic Modalities in Detecting Cardiovascular Complications of Thalassemia
Thalassemia major is the most common monogenetic disorder worldwide, manifested as chronic hemolytic anemia. This condition leads to the need for chronic blood transfusion to be monitored for an iron overload that may be stored in several tissues and organs, including cardiomyocytes, that might cause a broad spectrum of cardiac iron toxicities such as heart failure conduction delays, myocarditis, and arrhythmias. Non-invasive imaging modalities have their benefits and limitations. Each modality complements and generates a comprehensive diagnostic and monitoring of cardiac siderosis in thalassemia major patients.
- Open Access
- 27 December 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-8
Correlation between Serum Fatty Acid Binding Protein 4 (FABP4) Levels and Cardiac Function in Patients with Thalassemia Major
Background. Patients with thalassemia major may suffer from complications due to iron overload. It has been suggested that several adipokines may play a potential role in the development of complications in thalassemia. Fatty acid-binding protein 4 (FABP4) is one of the adipokines, bridging several aspects of metabolic and inflammatory pathways. Little is known about the relationship between this adipokine and cardiac and liver function, especially in patients with thalassemia major. Aims. This study is aimed at determining serum FABP4 levels in patients with thalassemia major and whether its concentration correlated with serum ferritin levels, as well as cardiac and liver function. Methods. Thalassemia major outpatients ( ) completed laboratory examination, echocardiography, and electrocardiography. Results. The mean age was years. A negative and weak correlation between serum ferritin and FABP4 was observed ( , ). In addition, there was moderate and positive correlation between left atrial volume index (LAVI) and FABP4 ( , ). Conclusions. Serum FABP4 correlated with serum ferritin and cardiac function in patients with thalassemia major. FABP4 may be a potential clinical biomarker for cardiac dysfunction via metabolic and inflammatory pathways due to iron accumulation and toxicity in patients with thalassemia major.
- 27 December 2021
- Published by Wiley in Disease Markers
- Vol. 2021, 1-8
Open AccessCorrelation between Serum Fatty Acid Binding Protein 4 (FABP4) Levels and Cardiac Function in Patients with Thalassemia Major
Background. Patients with thalassemia major may suffer from complications due to iron overload. It has been suggested that several adipokines may play a potential role in the development of complications in thalassemia. Fatty acid-binding protein 4 (FABP4) is one of the adipokines, bridging several aspects of metabolic and inflammatory pathways. Little is known about the relationship between this adipokine and cardiac and liver function, especially in patients with thalassemia major. Aims. This study is aimed at determining serum FABP4 levels in patients with thalassemia major and whether its concentration correlated with serum ferritin levels, as well as cardiac and liver function. Methods. Thalassemia major outpatients ( ) completed laboratory examination, echocardiography, and electrocardiography. Results. The mean age was years. A negative and weak correlation between serum ferritin and FABP4 was observed ( , ). In addition, there was moderate and positive correlation between left atrial volume index (LAVI) and FABP4 ( , ). Conclusions. Serum FABP4 correlated with serum ferritin and cardiac function in patients with thalassemia major. FABP4 may be a potential clinical biomarker for cardiac dysfunction via metabolic and inflammatory pathways due to iron accumulation and toxicity in patients with thalassemia major.
- Open Access
Iron Overload in Transfusion-Dependent Indonesian Thalassemic Patients
Thalassemia is a genetic disease caused by disruption of globin chain synthesis leading to severe anemia and thus regular blood transfusion is necessary. However, there have been known transfusions-related consequences, including iron overload and multi-organ damage. The aims of this study were to evaluate liver and cardiac function in youth and adult transfusion-dependent Indonesian thalassemic patients and to assess its correlation with serum ferritin levels, as well as T2magnetic resonance imaging (MRI). Transfusion-dependent thalassemic (TDT) outpatients (n = 66; mean age, 21.5 ± 7.2 years) were carried out for the complete assessment consisting of blood test including liver enzyme and serum ferritin, followed by electrocardiography (ECG) and echocardiography. Subjects were also divided by serum ferritin levels into three groups: < 2500 ng/mL, 2500–5000 ng/mL, and >5000 ng/mL. Additionally, subgroup analysis in patients with T2∗ MRI assessment was conducted. In terms of age of first blood transfusion, subjects with ferritin >5000 ng/mL were the youngest among others. The alanine aminotransferase (ALT) levels in group with serum ferritin >5000 ng/mL were significantly higher than those of the group with serum ferritin 5000 ng/mL had significantly lower tricuspid annular plane systolic excursion (TAPSE) when compared with those who had serum ferritin ∗ MRI was significantly lower than those without cardiac siderosis. There was significant, but only moderate correlation between serum ferritin and cardiac T2∗ MRI. Based on these findings, it is important to routinely monitor iron accumulation-related complications, including liver and cardiac damage in youth and adult TDT patients.
Open AccessIron Overload in Transfusion-Dependent Indonesian Thalassemic Patients
Thalassemia is a genetic disease caused by disruption of globin chain synthesis leading to severe anemia and thus regular blood transfusion is necessary. However, there have been known transfusions-related consequences, including iron overload and multi-organ damage. The aims of this study were to evaluate liver and cardiac function in youth and adult transfusion-dependent Indonesian thalassemic patients and to assess its correlation with serum ferritin levels, as well as T2magnetic resonance imaging (MRI). Transfusion-dependent thalassemic (TDT) outpatients (n = 66; mean age, 21.5 ± 7.2 years) were carried out for the complete assessment consisting of blood test including liver enzyme and serum ferritin, followed by electrocardiography (ECG) and echocardiography. Subjects were also divided by serum ferritin levels into three groups: < 2500 ng/mL, 2500–5000 ng/mL, and >5000 ng/mL. Additionally, subgroup analysis in patients with T2∗ MRI assessment was conducted. In terms of age of first blood transfusion, subjects with ferritin >5000 ng/mL were the youngest among others. The alanine aminotransferase (ALT) levels in group with serum ferritin >5000 ng/mL were significantly higher than those of the group with serum ferritin 5000 ng/mL had significantly lower tricuspid annular plane systolic excursion (TAPSE) when compared with those who had serum ferritin ∗ MRI was significantly lower than those without cardiac siderosis. There was significant, but only moderate correlation between serum ferritin and cardiac T2∗ MRI. Based on these findings, it is important to routinely monitor iron accumulation-related complications, including liver and cardiac damage in youth and adult TDT patients.